These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31814586)

  • 1. Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes.
    Heintjes EM; Houben E; Beekman-Hendriks WL; Lighaam E; Cremers SM; Penning-van Beest FJA; Stehouwer CDA; Herings RMC
    Neth J Med; 2019 Dec; 77(9):317-329. PubMed ID: 31814586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks.
    Sattar N; Rawshani A; Franzén S; Rawshani A; Svensson AM; Rosengren A; McGuire DK; Eliasson B; Gudbjörnsdottir S
    Circulation; 2019 May; 139(19):2228-2237. PubMed ID: 30955347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands.
    Heintjes E; Kuiper J; Lucius B; Penning-van Beest F; Kutikova L; Liem A; Herings R
    Curr Med Res Opin; 2017 Jan; 33(1):91-100. PubMed ID: 27646783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study.
    Toulis KA; Hanif W; Saravanan P; Willis BH; Marshall T; Kumarendran B; Gokhale K; Ghosh S; Cheng KK; Narendran P; Thomas GN; Nirantharakumar K
    Diabetes Metab; 2017 Jun; 43(3):211-216. PubMed ID: 28325589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
    Raee MR; Nargesi AA; Heidari B; Mansournia MA; Larry M; Rabizadeh S; Zarifkar M; Esteghamati A; Nakhjavani M
    Arch Iran Med; 2017 Mar; 20(3):141-146. PubMed ID: 28287807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of type 2 diabetes mellitus on in-hospital-mortality after major cardiovascular events in Spain (2002-2014).
    de Miguel-Yanes JM; Jiménez-García R; Hernández-Barrera V; Méndez-Bailón M; de Miguel-Díez J; Lopez-de-Andrés A
    Cardiovasc Diabetol; 2017 Oct; 16(1):126. PubMed ID: 29017514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.
    Engelen SE; van der Graaf Y; Stam-Slob MC; Grobbee DE; Cramer MJ; Kappelle LJ; de Borst GJ; Visseren FLJ; Westerink J;
    Int J Cardiol; 2017 Dec; 248():301-307. PubMed ID: 28802735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study.
    Wan EYF; Fong DYT; Fung CSC; Yu EYT; Chin WY; Chan AKC; Lam CLK
    Diabetes Obes Metab; 2018 Feb; 20(2):309-318. PubMed ID: 28722290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
    J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
    Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
    Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.
    Komaru Y; Takeuchi T; Suzuki L; Asano T; Urayama KY
    J Diabetes Complications; 2020 Mar; 34(3):107511. PubMed ID: 31928892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
    Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
    Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.